Dr. Hemant Kumar Bid

Georgia Medical Cannabis Society, Inc., USA

Saint Louis University, USA

Email: hemant.bid@slu.edu, hk_bid@cdri.res.in

Qualifications

2019 M.Sc., The Ohio State University, USA

2006 Ph.D., Kanpur University, INDIA

2001 M.Sc., Dr R M L Avadh University, INDIA

Publications (Selected)

1. Wang, B., Hsu, S. H., Wang, X., Kutay, H., Bid, H. K., Yu, J., ... & Ghoshal, K. (2025). Erratum: Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: Role of E2F1 and transcription factor dimerization partner 2. Hepatology, 81(6), E176.
2. Shackleford, T. J., Hariharan, S., Vaseva, A. V., Alagoa, K., Espinoza, M., Bid, H. K., ... & Houghton, P. J. (2023). Redundant signaling as the predominant mechanism for resistance to antibodies targeting the type-I insulin-like growth factor receptor in cells derived from childhood sarcoma. Molecular cancer therapeutics, 22(4), 539-550.
3. Khurshid, S., Montes, M., Comiskey Jr, D. F., Shane, B., Matsa, E., Jung, F., ... & Chandler, D. (2022). Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma. NPJ Precision Oncology, 6(1), 1.
4. Kumar, A., Tripathi, V. D., Kumar, P., Gupta, L. P., Trivedi, R., Bid, H., ... & Chattopadhyay, N. (2019). Corrigendum to “Design and synthesis of 1, 3-biarylsulfanyl derivatives as new anti-breast cancer agents”[Bioorg. Med. Chem. 19 (2011) 5409–5419]. Bioorganic & Medicinal Chemistry, 27(17), 3960-3961.
5. Gross, A. C., Cam, H., Phelps, D. A., Saraf, A. J., Bid, H. K., Cam, M., ... & Roberts, R. D. (2018). IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. JCI insight, 3(16), e99791.
6. Lopez, G., Braggio, D., Zewdu, A., Casadei, L., Batte, K., Bid, H. K., ... & Pollock, R. (2017). Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates. PLoS One, 12(11), e0188859.
7. Bid HK, Phelps DA, Xiao L, Guttridge DC, Lin J, London C, Baker LH, Mo X, Houghton PJ. The Bromodomain BET inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther. 2016 May; 15(5):1018-28. PMID: 26908627
8. Bid, H. K., Phelps, D. A., Xaio, L., Guttridge, D. C., Lin, J., London, C., ... & Houghton, P. J. (2016). The bromodomain BET inhibitor JQ1 suppresses tumor angiogenesis in models of childhood sarcoma. Molecular cancer therapeutics, 15(5), 1018-1028.
9. Bid, H. K., Roberts, R. D., Cam, M., Audino, A., Kurmasheva, R. T., Lin, J., ... & Cam, H. (2014). ΔNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis. Cancer research, 74(1), 320-329.
10. Bid, H. K., Kibler, A., Phelps, D. A., Manap, S., Xiao, L., Lin, J., ... & Houghton, P. J. (2013). Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clinical Cancer Research, 19(24), 6716-6729.
11. Bid, H. K., Oswald, D., Li, C., London, C. A., Lin, J., & Houghton, P. J. (2012). Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PloS one, 7(4), e35513.
12. Bid, H. K., London, C. A., Gao, J., Zhong, H., Hollingsworth, R. E., Fernandez, S., ... & Houghton, P. J. (2013). Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy. Clinical Cancer Research, 19(11), 2984-2994.
13. Bid, H. K., Zhan, J., Phelps, D. A., Kurmasheva, R. T., & Houghton, P. J. (2012). Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Molecular cancer therapeutics, 11(3), 649-659.

Profile Details

https://www.slu.edu/professional-studies/contact-us/faculty/bid-hemant-kumar.php

https://www.linkedin.com/in/hemant-kumar-bid-bs-ms-phd-ms-pharmacology-60aabb15/

https://www.researchgate.net/scientific-contributions/Hemant-Kumar-Bid-39130564